Cargando…

Imaging endpoints for clinical trial use: a RECIST perspective

Twenty years after its initial introduction, Response Evaluation Criteria in Solid Tumors (RECIST) remains today a unique standardized tool allowing uniform objective evaluation of response in solid tumors in clinical trials across different treatment indications. Several attempts have been made to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Litière, Saskia, Bogaerts, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693866/ https://www.ncbi.nlm.nih.gov/pubmed/36424032 http://dx.doi.org/10.1136/jitc-2022-005092

Ejemplares similares

Improving phase ii oncology trial using best observed RECIST response as an endpoint by modelling continuous tumour measurements
por: Lin, Chien-Ju, et al.
Publicado: (2015)

Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements
por: Lin, Chien‐Ju, et al.
Publicado: (2017)

Imaging biomarkers for evaluating tumor response: RECIST and beyond
por: Ko, Ching-Chung, et al.
Publicado: (2021)

Imaging endpoints for clinical trials in Alzheimer’s disease
por: Cash, David M, et al.
Publicado: (2014)

iRECIST: how to do it
por: Persigehl, Thorsten, et al.
Publicado: (2020)

Imaging tumour response: beyond RECIST
por: Koh, Dow-Mu
Publicado: (2014)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
por: van Persijn van Meerten, Els L., et al.
Publicado: (2009)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective
por: Stephenson, Diane, et al.
Publicado: (2021)

Imaging beyond RECIST: CT and MRI in molecular therapies
por: Diederich, Stefan
Publicado: (2012)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
por: Kim, Jung Han, et al.
Publicado: (2015)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

iRECIST and atypical patterns of response to immuno-oncology drugs
por: Ramon-Patino, Jorge Luis, et al.
Publicado: (2022)

RECIST Applied to Realistic Tumor Models
por: Levine, Zachary H., et al.
Publicado: (2011)

Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series
por: McDonald, James, et al.
Publicado: (2023)

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

Binary surrogate endpoints in clinical trials from the perspective of case definitions
por: HAHN, ANDREAS, et al.
Publicado: (2021)

A Letter in Support of Real-World RECIST
por: Gajra, Ajeet, et al.
Publicado: (2020)

Understanding the Use of Composite Endpoints in Clinical Trials
por: McCoy, C. Eric
Publicado: (2018)

Informative noncompliance in endpoint trials
por: Snapinn, Steven M, et al.
Publicado: (2004)

Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy
por: Choi, Hyun Chang, et al.
Publicado: (2015)

Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?
por: Beaumont, Hubert, et al.
Publicado: (2023)

Cardiac magnetic resonance imaging parameters as surrogate endpoints in clinical trials of acute myocardial infarction
por: Desch, Steffen, et al.
Publicado: (2011)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

Multilingual RECIST classification of radiology reports using supervised learning
por: Mottin, Luc, et al.
Publicado: (2023)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

Evaluation of the True Endpoint of Clinical Trials for Cancer Cachexia
por: Naito, Tateaki
Publicado: (2019)

RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
por: Iannessi, Antoine, et al.
Publicado: (2021)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

Improved Endpoints for Cancer Immunotherapy Trials
por: Hoos, Axel, et al.
Publicado: (2010)

Radiomic and Volumetric Measurements as Clinical Trial Endpoints—A Comprehensive Review
por: Funingana, Ionut-Gabriel, et al.
Publicado: (2022)

IPF clinical trial design and endpoints
por: Nathan, Steven D., et al.
Publicado: (2014)

The Importance of Endpoints in Oncology Clinical Trials
por: Faiman, Beth
Publicado: (2023)

Are component endpoints equal? A preference study into the practice of composite endpoints in clinical trials
por: Vaanholt, Melissa C.W., et al.
Publicado: (2018)

Discrepancies of assessments in a RECIST 1.1 phase II clinical trial – association between adjudication rate and variability in images and tumors selection
por: Beaumont, Hubert, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h9b7fbc4uj49527qauhgjqkf01